OR WAIT null SECS
For the first time, 17 of Advanstar Communications' Life Sciences publications and its web portal, ModernMedicine.com, are collaborating in a coordinated, interdisciplinary initiative to address a major public health issue: cardiometabolic disorders and weight.
This groundbreaking initiative emphasizes core competencies, best practices, and shared responsibility among all stakeholders in the patient's healthcare ecosystem. We investigate cardiometabolic disorders and how they interrelate to significantly increase cardiovascular risk. We provide the tools and information that primary care physicians, specialists, midlevels, nurses, pharmacists, managed care professionals, and the pharmaceutical industry need to work together to address this growing problem and ultimately improve patient outcomes.
This month through November, the project will be featured on Advanstar's ModernMedicine Network, in our 15 healthcare publications-Medical Economics, Contemporary OB/GYN, Contemporary Pediatrics, Geriatrics, Formulary, Drug Topics, Managed Healthcare Executive, Ophthalmology Times, Optometry Times, Dermatology Times, Cosmetic Surgery Times, Urology Times,RN, Healthcare Traveler, and LocumLife-and in 2 of our pharmaceutical publications, Pharmaceutical Executive and Applied Clinical Trials. (Learn more about each publication on page 11.) With 340,000 plus members on the ModernMedicine Network and a combined print and digital edition circulation of more than 1 million, these brands provide the news, analysis, and education that healthcare professionals and executives and pharmaceutical industry leaders alike have come to rely on.
The public health impact of cardiometabolic abnormalities becomes clearer when one considers that 38.9 percent of U.S. adults report a prescription drug expense for a cardiovascular agent and 28.9 percent report a prescription drug expense for a metabolic agent. Furthermore, metabolic agents are the No. 1 type of medication prescribed in the United States, accounting for an expenditure of $38.1 billion annually, and cardiovascular agents rank No. 2 at $33.1 billion annually.3